A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Clinical trial NCT05120349 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05120349
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-21
- Primary completion
- 2027-08-02
- Enrollment
- 390
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.